Vigilant Biosciences Announces Agreement with Biotech-IgG AB for Exclusive Distribution of the OncAlert™ Oral Cancer Product Line in Scandinavia

March 11, 2015
COLOGNE, Germany

Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today that it has entered into a three-year exclusive sales and marketing agreement with Biotech-IgG AB for the distribution of the OncAlert™ Oral Cancer product line in Denmark, Norway and Sweden. The OncAlert Oral Cancer product line includes a rapid test (OncAlert Oral Cancer RAPID Test) and a quantitative, laboratory test (OncAlert Oral Cancer LAB Test).

Under the terms of the agreement, Biotech-IgG AB will exclusively market and sell the OncAlert RAPID Test and OncAlert LAB Test to the dental and oncology markets in Scandinavia, pursuant to the CE Mark registration approvals of the products, which are expected in Q1 2016. Financial terms were not disclosed.

Headquartered in Lund, Sweden, Biotech-IgG AB is a leading supplier of products for medical diagnostics and research, routine, and process applications for the life science industry.

“Our agreement with Biotech-IgG for the sale of our OncAlert products in Scandinavia represents our first European Union market partner and is a significant step for Vigilant as we prepare to launch our oral cancer testsglobally through strategic commercialization partnerships,” said Matthew H.J. Kim, Founder, Chairman, and CEO of Vigilant Biosciences, Inc. “Hundreds of thousands of people continue to suffer from this disease each year, and many are diagnosed when the cancer is already at a late stage. Our mission is to work with our worldwide partners, such as Biotech-IgG, to enhance the lives of patients by providing products that enable earlier detection and intervention.”

“We are pleased to be named the exclusive distributor of the OncAlert product line in the Scandinavian market,” said Dario Kriz, Ph.D., CEO of Biotech-IgG AB. “These innovative, and effective tests will provide healthcare professionals with an accurate and quick aid in the diagnosis of oral cancer in their patients. There is currently no other solution on the market that takes this approach to oral cancer detection, and we are confident that it will help save lives.”

Vigilant Biosciences’ initial products, the OncAlert Oral Cancer RAPID Test (“OncAlert RAPID Test”) and the OncAlert Oral Cancer LAB Test (“OncAlert LAB Test”), are the first and only technologies that measure soluble CD44 and total protein levels – protein markers clinically shown to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. Both products use a simple, oral rinse collection and measurement procedure that is easy to administer and non-invasive for the patient. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus). The OncAlert LAB Test is CE Marked. The OncAlert RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time. The OncAlert Oral Cancer product line is not yet available for sale in the U.S.

About Oral Cancer
According to the Oral Cancer Foundation, there are over 640,000 new cases of oral cancer each year worldwide. In the U.S., close to 48,250 individuals will be diagnosed with oral or pharyngeal cancer this year, with 9,575 deaths from the disease, killing roughly one person per hour, 24 hours per day. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.

About Biotech-IgG
Biotech-IgG is a supplier of a wide range of high quality products for medical diagnostics and research, routine and process applications for life science and food industries. Biotech-IgG Group’s vision is to become the leading Scandinavian distributor of immune diagnostics and life science products to the healthcare industry and also offers a full line of proprietary products for a well-defined group of customers operating in the production, development and analysis of proteins, mainly antibodies.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Vigilant’s OncAlert Oral Cancer product line includes rapid and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The OncAlert Oral Cancer product line is not yet available for sale in the U.S. For more information, visit

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev2